NYLIM
SPRY icon

New York Life Investment Management’s ARS Pharmaceuticals SPRY Stock Holding History

New York Life Investment Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-161,617
Closed -$1.38M – 1373
2022
Q4 		$1.38M Buy
161,617
+17,339
+12% +$113K 0.02% 582
2022
Q3 		$762K Buy
144,278
+11,418
+9% +$56.3K 0.01% 642
2022
Q2 		$563K Buy
+132,860
New +$463K 0.01% 680

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York Life Investment Management's SPRY Position: Q1 2023 in Review

New York Life Investment Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2023, closing a stake of 161,617 shares — an estimated $1.38M sold.

New York Life Investment Management first reported a position in SPRY in Q2 2022 and held it in 3 quarters. The position peaked at $1.38M in Q4 2022. 89 funds tracked by Wall St. Rank hold SPRY as of Q1 2023.

  • New York Life Investment Management reported no remaining ARS Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 161,617 ARS Pharmaceuticals shares in Q1 2023, an estimated $1.38M.
  • New York Life Investment Management first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's ARS Pharmaceuticals position peaked at $1.38M in Q4 2022.
  • 89 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.